Coronavirus Update: FDA adds Merck antiviral to COVID-19 tool kit for high-risk adults above 18, amid flurry of positive news on boostersMarket Watch • 12/23/21
FDA authorizes Merck's COVID-19 antiviral but only when other treatments are 'not accessible' or 'appropriate'Market Watch • 12/23/21
FDA To Possibly Authorize Pfizer, Merck COVID-19 Antiviral Pills This Week: BloombergBenzinga • 12/22/21
Merck and Ridgeback Biotherapeutics say UK government has ordered additional 1.75 million doses of their COVID antiviralMarket Watch • 12/22/21
Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of MolnupiravirBusiness Wire • 12/22/21
Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord TherapeuticsBusiness Wire • 12/21/21
BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumabAccesswire • 12/17/21
EMA's CHMP Backs Approval For Merck's Keytruda In Adjuvant Setting For Kidney CancerBenzinga • 12/17/21
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following SurgeryBusiness Wire • 12/17/21
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of MedicineBusiness Wire • 12/16/21
ADDING and REPLACING European Commission Approves Merck's VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and OlderBusiness Wire • 12/15/21
European Commission Approves Merck's VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and OlderBusiness Wire • 12/15/21